FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)  P&T Community Novartis anemia drug gets FDA priority review  MarketWatchFull coverage

Read More ...
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA) published May 30, 2018 at 01:19PM. Original Source Link : https://www.ptcommunity.com/wire/fda-expedites-review-novartis-drug-promacta-first-line-severe-aplastic-anemia-saa

loading...